Prevention and Management of Radiation Dermatitis: Variation Based on Anatomic Target
Main Article Content
Keywords
Radiation Dermatitis, Superfical Radiation Therapy, SRT, non melanoma skin cancer, NMSC
Abstract
Radiation dermatitis (RD) is a universal adverse consequence of radiation therapy (RT) and is associated with a dramatic barrier dysfunction and inflammation. The management of RD depends upon the anatomic target: internal malignancy (IM) versus skin cancer (NMSC). For IM, it is critical to address RD for both morbidity and the ability to continue treatment. While multiple treatment options exist, barrier repair using a ceramide dominant triple lipid prescription formulation has been shown to have significant benefit. For NMSC, radiation dermatitis is a necessary side effect potentially increasing the effect of radiation therapy. Barrier repair should occur after treatment is completed.
References
2. Sharma A, Birnie AJ, Bordea C, et al. British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease) 2022. Br J Dermatol. 2023;188(2):186-194. doi:10.1093/bjd/ljac042
3. Nestor MS, Han H, Ceci FM, Lawson A, Gade A. Evaluating the safety and
efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. J Cosmet Dermatol. 2023;22(9):2471-2475. doi:10.1111/jocd.15886
4. Nestor MS, Berman B, Patel J, Lawson A. Safety and Efficacy of Aminolevulinic Acid 10% Topical Gel versus Aminolevulinic Acid 20% Topical Solution Followed by Blue-light Photodynamic Therapy for the Treatment of Actinic Keratosis on the Face and Scalp: A Randomized, Double-blind Study. J Clin Aesthet Dermatol. 2019;12(3):32-38.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.